Sublingual buprenorphine for chronic pain: A survey of clinician prescribing practices

Clinical Journal of Pain

Volumn 30, Issue 4, 2014, Pages 295-300

  Rosen, Kristen ^a   Gutierrez, Antonio ^a   Haller, Deborah ^b   Potter, Jennifer S ^a,c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

attitudes; chronic pain; opioids; practices; sublingual buprenorphine

Indexed keywords

BUPRENORPHINE; NALOXONE; OPIATE;

CHRONIC PAIN; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL SOCIETY; OPIATE ADDICTION; PHYSICIAN ATTITUDE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REVIEW; SUBSTANCE ABUSE;

ADMINISTRATION, SUBLINGUAL; ANALGESICS, OPIOID; BUPRENORPHINE; CHRONIC PAIN; FEMALE; HEALTH SURVEYS; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PRESCRIPTION DRUGS; UNITED STATES;

EID: 84896389682     PISSN: 07498047     EISSN: 15365409     Source Type: Journal    
DOI: 10.1097/AJP.0b013e318298ddad     Document Type: Review

References (21)

1. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment Improvement Protocol (TIP) Series 40. HHS
2. Publication No. (SMA) 04-3939. Rockville, MD: Substance Abuse and Mental Health Services Administration. 2004. Available at: http://store.samhsa.gov/ shin/content//SMA12-4682/SMA12-4682.pdf. Accessed November 16, 2012.
3. Harris DS, Jones RT, Welm S, et al. Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine. Drug Alcohol Depend. 2000;61:85-94.
4. Johnson RE, Fudala PJ, Payne R. Buprenorphine: consideration for pain management. J Pain Symptom Manage. 2005; 29:297-318.
5. Heit HA, Gourlay DL. Buprenorphine: new tricks with an old molecule for pain management. Clin J Pain. 2008; 24:93-97.
6. Malinoff HL, Barkin RL, Wilson G. Sublingual buprenor-phine is effective in the treatment of chronic pain syndrome. Am J Ther. 2005;12:379-384.
7. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70:S59-S77.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Text rev. 4th ed. Washington, DC: American Psychiatric Association; 2000.
9. Substance Abuse and Mental Health Services Administration [SAMHSA]. The Drug Addiction Treatment Act of 2000 (DATA 2000). Available at: http://buprenorphine.samhsa. gov/index.html. Accessed November 9, 2012.
10. Schnoll SH. Treatment of opioid addiction in physician's offices: it's about time. J Addict Dis. 2001;20:1-3.
11. Dodrill CL, Helmer DA, Kosten TR. Prescription pain medication dependence. Am J Psychiatry. 2011;168:466-471
12. Heit HA, Covington E, Good PM. Dear DEA. Pain Med. 2004;5:303-308.
13. Heit HA, Gourlay DL. Buprenorphine in pain and addiction. In: Smith H, Passik SD, eds. Pain and Chemical Dependency. New York: Oxford University Press; 2008:303-307.
14. Lin JJ, Alfandre D, Moore C. Physician attitudes toward opioid prescribing for patients with persistent noncancer pain. Clin J Pain. 2007;23:799-803.
15. Bhamb B, Brown D, Hariharan J, et al. Survey of select practice behaviors by primary care physicians on the use of opioids for chronic pain. Curr Med Res Opin. 2006;22:1859-1865.
16. Weinstein SM, Laux LF, Thornby JI, et al. Physicians' attitudes toward pain and the use of opioid analgesics: results of a survey from the Texas Cancer Pain Initiative. South Med J. 2000;93:479-487.
17. Campbell EG, Gruen RL, Mountford J, et al. A national survey of physician-industry relationships. N Engl J Med. 2007;356: 1742-1750.
18. American Pain Society. American Pain Society 2010 Annual Report, 2010. Available at: http://www.americanpainsociety.org/uploads/pdfs/annual-report2010. pdf. Accessed May 16, 2011.
19. Potter M, Schafer S, Gonzalez-Mendez E, et al. Opioids for chronic nonmalignant pain. J Fam Pract. 2001;50:145-151.
20. Suboxone (buprenorphine and naloxone) sublingual film CIII Buprenorphine (opioid partial agonist-antagonist) Naloxone (opioid antagonist): initial REMS approval August 30, 2010. Available at: http://www.fda.gov/downloads/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM 227949.pdf. Accessed November 5, 2012.
21. Butrans (buprenorphine) transdermal system partial opioid agonist: risk evaluation and mitigation strategy (REMS). (2010). Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsand Providers/UCM220880.pdf. Accessed March 6, 2013.